Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NASDAQ:ETNB NASDAQ:SYRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$30.95-0.7%$27.31$4.97▼$45.50$130.88M2.45125,288 shs135,939 shsETNB89BIO$14.84$14.82$6.55▼$15.06$2.20B1.273.57 million shs55.65 million shsSYRSSyros Pharmaceuticals$0.00+100.0%$0.00$0.00▼$0.03$5K1.3117,514 shs17,524 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-0.67%+0.10%+8.19%-94.87%-96.18%ETNB89BIO0.00%0.00%0.00%0.00%+41.47%SYRSSyros Pharmaceuticals+100.00%+100.00%+100.00%0.00%-98.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$30.95-0.7%$27.31$4.97▼$45.50$130.88M2.45125,288 shs135,939 shsETNB89BIO$14.84$14.82$6.55▼$15.06$2.20B1.273.57 million shs55.65 million shsSYRSSyros Pharmaceuticals$0.00+100.0%$0.00$0.00▼$0.03$5K1.3117,514 shs17,524 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-0.67%+0.10%+8.19%-94.87%-96.18%ETNB89BIO0.00%0.00%0.00%0.00%+41.47%SYRSSyros Pharmaceuticals+100.00%+100.00%+100.00%0.00%-98.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/AETNB89BIO 2.00Hold$18.1722.42% UpsideSYRSSyros Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CUE, ETNB, and SYRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M4.73N/AN/A$10.08 per share3.07ETNB89BION/AN/AN/AN/A$3.34 per shareN/ASYRSSyros Pharmaceuticals$386K0.01N/AN/A$0.79 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$5.58N/AN/AN/A-59.65%-98.30%-53.69%8/18/2026 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%N/ASYRSSyros Pharmaceuticals-$164.57M-$3.03N/AN/AN/AN/A-3,369.56%-97.04%7/29/2026 (Estimated)Latest CUE, ETNB, and SYRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q2 2026CUECue Biopharma-$1.69N/AN/AN/A$3.00 millionN/A5/14/2026Q1 2026CUECue Biopharma-$3.30-$1.08+$2.22-$1.08$2.50 million$5.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A3.573.57ETNB89BIO0.0715.1915.19SYRSSyros PharmaceuticalsN/A2.252.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%ETNB89BION/ASYRSSyros Pharmaceuticals91.47%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma14.56%ETNB89BIO2.60%SYRSSyros Pharmaceuticals12.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma604.20 million3.59 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableSYRSSyros Pharmaceuticals12026.83 million23.54 millionNo DataCUE, ETNB, and SYRS HeadlinesRecent News About These CompaniesFinancial Survey: Actinium Pharmaceuticals (NYSE:ATNM) and Syros Pharmaceuticals (NASDAQ:SYRS)July 18 at 2:14 AM | americanbankingnews.comSyros Announces Pricing of $75.6 Million Public Offering of Common StockJuly 14, 2026 | businesswire.comRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comSyros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 29, 2025 | msn.comSyros Pharmaceuticals Inc (SYRS) Stock Price Reaches $0.22: What Factors Are Influencing This Level?January 18, 2025 | bovnews.comBWhat’s Causing Syros Pharmaceuticals Inc (SYRS) Stock’s -96.35% Drop Over the Last Six Months?January 16, 2025 | bovnews.comBSYRS’s Latest Surge: What’s Behind the Spike?January 6, 2025 | bovnews.comBThe SYRS Conundrum: Why Syros Pharmaceuticals Inc’s Stock Is Making Headlines AgainJanuary 2, 2025 | bovnews.comBAnalysts Predict a $15 Target for Syros Pharmaceuticals Inc (SYRS) Stock—What Could Drive It There?December 31, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock: More Resilient Than It AppearsDecember 27, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock Dive: The Hidden Causes RevealedDecember 26, 2024 | bovnews.comBWhat’s Fueling Syros Pharmaceuticals Inc (SYRS) Stock’s -94.59% Loss Below Its 200-Day SMA?December 14, 2024 | bovnews.comBSyros Pharmaceuticals Inc (SYRS) Stock Settles at $0.24: What’s Contributing to This Price Point?December 7, 2024 | bovnews.comBWhy Did Syros Pharmaceuticals Inc (SYRS) Stock Plunge -1.67% Last Week?December 5, 2024 | bovnews.comBNancy A. Simonian Sells 37,070 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) StockDecember 5, 2024 | insidertrades.comSyros Pharmaceuticals Inc (SYRS) Stock Rated Buy by H.C. WainwrightDecember 2, 2024 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]By MarketBeat Staff | July 7, 2026CUE, ETNB, and SYRS Company DescriptionsCue Biopharma NASDAQ:CUE$30.95 -0.21 (-0.67%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$30.42 -0.53 (-1.70%) As of 07/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.89BIO NASDAQ:ETNB89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Syros Pharmaceuticals NASDAQ:SYRS$0.0002 +0.00 (+100.00%) As of 07/20/2026 11:22 AM EasternSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
